BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 28373440)

  • 1. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
    World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
    Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
    Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal Transition (EMT) is Correlated with Patient's Prognosis of Lung Squamous Cell Carcinoma.
    Aruga N; Kijima H; Masuda R; Onozawa H; Yoshizawa T; Tanaka M; Inokuchi S; Iwazaki M
    Tokai J Exp Clin Med; 2018 Apr; 43(1):5-13. PubMed ID: 29637533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.
    Sung WJ; Park KS; Kwak SG; Hyun DS; Jang JS; Park KK
    Int J Clin Exp Pathol; 2015; 8(8):8997-9009. PubMed ID: 26464642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of epithelial-mesenchymal transition-related markers between cancer tissue and tumor emboli].
    He N; Wu GF; Zhao HY; Han HX
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):758-61. PubMed ID: 22336160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Krüppel-Like Factor 8 Overexpression Correlates with Poor Prognosis in Non-Small Cell Lung Cancer.
    Li J; Liu Y; Xue J; Xu M; Zhang J; Liu J; Wang W
    Pathol Oncol Res; 2019 Jan; 25(1):115-121. PubMed ID: 28986741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
    Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
    Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.
    Pore M; Meijer C; de Bock GH; Boersma-van Ek W; Terstappen LW; Groen HJ; Timens W; Kruyt FA; Hiltermann TJ
    Clin Lung Cancer; 2016 Nov; 17(6):535-542. PubMed ID: 27363902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.
    Kim SH; Kim JM; Shin MH; Kim CW; Huang SM; Kang DW; Suh KS; Yi ES; Kim KH
    Histol Histopathol; 2012 May; 27(5):581-91. PubMed ID: 22419022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
    Ibrahim R; Matsubara D; Osman W; Morikawa T; Goto A; Morita S; Ishikawa S; Aburatani H; Takai D; Nakajima J; Fukayama M; Niki T; Murakami Y
    Hum Pathol; 2014 Jul; 45(7):1397-405. PubMed ID: 24775604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
    Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulated vimentin and upregulated E-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?
    Luo T; Wang L; Wu P; Gong W; Chen W; Zhao H; Zheng Z
    Neoplasma; 2017; 64(5):693-699. PubMed ID: 28592120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
    PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C
    J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of mesenchymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma.
    Sudo T; Iwaya T; Nishida N; Sawada G; Takahashi Y; Ishibashi M; Shibata K; Fujita H; Shirouzu K; Mori M; Mimori K
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S324-35. PubMed ID: 22644514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.
    Matsubara T; Tagawa T; Takada K; Toyokawa G; Shimokawa M; Kozuma Y; Akamine T; Haro A; Osoegawa A; Mori M
    Clin Lung Cancer; 2019 Jul; 20(4):e504-e513. PubMed ID: 31103348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
    Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
    World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.